Nitrogen Use in pharmaceutical Production

Recommendation
16-18 September 2025
Barcelona, Spain
Organisation of a GMP-compliant Site Change
Nitrogen often comes in contact with a product during manufacturing and is therefore relevant for its quality, especially when it comes to the manufacture of sterile products. Nonetheless, the use of nitrogen is significantly less specified than that of pharmaceutical water. Parameters and limits have to be defined by the pharmaceutical users themselves.
Like with pharmaceutical water, the first sources of information are pharmacopoeias. The European Pharmacopoeia defines two types of nitrogen: “medical nitrogen” and “nitrogen with low oxygen content”. As the name suggests, the first is used for medical purposes, e.g. in hospitals. The latter can be used for the inertisation of oxygen-sensitive pharmaceuticals, for example. There are no parameters for water content, oil or particles, however. It seems inadequate that the only specification is 99.5% purity for nitrogen with low oxygen content. The remaining 0.5% could, depending on manufacture, storage and distribution, very well consist of water, oil, etc.
This nitrogen quality is also interesting when it comes to the use of nitrogen generators (molecular sieve technique), though. Those can be a suitable alternative for the well-known compressed-gas bottles in many use cases.
As is the case with compressed air (see also Requirements for compressed Air in the Pharmaceutical Industry), the pharmaceutical user has to define their own specifications depending on application and product risk. The 2010 ISO 8573-1 can be useful here. A specification according to class 2 is helpful in most cases – this excludes particles > 5 µm. Microbiological limits can be defined in accord with the class of purity in which the nitrogen is being applied.
In conclusion, nitrogen may be seen as an excipient, even though the amount of it remaining in a finished product is insignificant compared to classic excipients like lactose. Therefore, the EG Guideline 2015/C 95/02 can be consulted for risk assessment concerning contamination or for qualification requirements
Related GMP News
25.06.2025Deficiencies in the Water System: Warning Letter to US Manufacturers of OTC Products
11.06.2025Warning Letter to Chinese Manufacturer due to serious Sterility and Hygiene Deficiencies
04.06.2025FAQs regarding Cross Contamination
04.06.2025GMP Deficiencies at French Sterile Manufacturer
14.05.2025Process Validation and Pharmaceutical Water Deficiencies at a US Manufacturer
07.05.2025Another FDA Warning Letter for Indian API manufacturer